Press Releases

SAN FRANCISCO --(BUSINESS WIRE)--May 5, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its first

First Study of Nutritional Cognitive Behavioral Therapy for Fatty Liver Disease and Expanded Real-World Evidence Studies for Type 2 Diabetes Follow Promising Primary Endpoint Clinical Trial Data SAN FRANCISCO --(BUSINESS WIRE)--Apr. 6, 2022-- Better Therapeutics, Inc.

SAN FRANCISCO --(BUSINESS WIRE)--Apr. 4, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum ,

Company Highlights Positive Pivotal Clinical Trial Data for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes SAN FRANCISCO --(BUSINESS WIRE)--Mar. 28, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive

Leading Medical Experts to Discuss Top-Line Results Showing Significant Glycemic Improvement Using BT-001 SAN FRANCISCO --(BUSINESS WIRE)--Mar. 23, 2022-- Better Therapeutics, Inc . (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive

Data Demonstrates Clinically Meaningful and Statistically Significant Results, Improving Glycemic Control by Reducing A1c 0.4% Versus the Control Group Receiving Standard of Care SAN FRANCISCO --(BUSINESS WIRE)--Mar. 15, 2022-- Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a

Medical experts discuss the potential use of prescription digital therapeutics (PDTs) delivering cognitive behavior therapy to address behavioral root causes of disease The role of data generated through randomized, controlled trials and real-world evidence studies on payer coverage and

Major step forward towards reimbursement for software-based treatments including Better Therapeutics’ BT-001 for the treatment of type 2 diabetes SAN FRANCISCO --(BUSINESS WIRE)--Feb. 28, 2022-- Better Therapeutics, Inc . (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics

Open-label, randomized, controlled study will evaluate BT-001, a prescription digital therapeutic (PDT) delivering cognitive behavioral therapy to address behavioral root cause of type 2 diabetes Multi-year study will evaluate effectiveness, durability, healthcare utilization and medication changes

SAN FRANCISCO --(BUSINESS WIRE)--Jan. 20, 2022-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum ,